GWLL Stock Overview
Focuses on nutraceutical and dietary supplements business in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Goldenwell Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$0.33 |
| 52 Week Low | US$0.059 |
| Beta | 2.72 |
| 1 Month Change | 0% |
| 3 Month Change | -11.11% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| GWLL | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 2.8% |
| 1Y | n/a | -25.5% | 24.6% |
Return vs Industry: Insufficient data to determine how GWLL performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how GWLL performed against the US Market.
Price Volatility
| GWLL volatility | |
|---|---|
| GWLL Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GWLL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GWLL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Shuang Liu | n/a |
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI—bovine cardiac vascular active peptide; Double Proline AG – 3D active collagen peptide; cartilage peptide, a type II collagen peptide; Se Plus tablets and sugar master tablets. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech, Inc. Fundamentals Summary
| GWLL fundamental statistics | |
|---|---|
| Market cap | US$19.80m |
| Earnings (TTM) | -US$137.10k |
| Revenue (TTM) | US$939.00 |
Over9,999x
P/S Ratio-144.4x
P/E RatioIs GWLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GWLL income statement (TTM) | |
|---|---|
| Revenue | US$939.00 |
| Cost of Revenue | US$531.00 |
| Gross Profit | US$408.00 |
| Other Expenses | US$137.51k |
| Earnings | -US$137.10k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0014 |
| Gross Margin | 43.45% |
| Net Profit Margin | -14,600.85% |
| Debt/Equity Ratio | 0% |
How did GWLL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/24 18:17 |
| End of Day Share Price | 2024/06/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Goldenwell Biotech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|